The following trials provide information to treat various types of respiratory and inflammatory diseases, both for ongoing and completed clinical trials. For more information on both of these therapy areas please click here.
- collapse A phase II, double-blind, placebo-controlled, randomised, 6-way cross-over, single-dose study to investigate the local and systemic effects of 3 doses of inhaled AZD3199 (a β2-agonist) compared to formoterol in asthmatic patients
- collapse Symbicort Turbuhaler 30/60 Clinical Experience Investigation
- collapse A Phase 2, randomized, blinded, 5-period cross-over, placebo and active controlled, multicenter, dose-finding study comparing single doses of formoterol 2.25 μg, 4.5 μg, and 9 μg delivered via Symbicort pMDI and Foradil® 12 μg evaluating the relative bronchodilating effects and safety in children
- collapse Magnitude of Osteoarthritis disadVantage on pEoples liveS
- collapse Asthma Control Study 2011
- collapse Asthma control and clinical practice in Hungary 2009
- collapse A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan
- collapse Descriptive pharmacoepidemiological study on the use of Symbicort Turbuhaler in the treatment of asthma in France and impact of a new therapeutic strategy on the compliance and control of asthma
- collapse Impact of Morning Symptoms in Clinical Control of COPD
- collapse An open phase III, multi-centre 52-week, parallel-group study evaluating the safety and efficacy of formoterol 18 ?g daily dose compared with standard COPD treatment, in Japanese patients with chronic obstructive pulmonary disease (COPD)
